| |
Baseline BMI (kg/m2)
|
---|
< 25
|
25–29
|
≥ 30
|
---|
RR
|
95% CI
|
RR
|
95% CI
|
RR
|
95% CI
|
---|
BMI at 20 (kg/m2)
| | | | | | |
< 25
|
Nocturiaa
|
1.00
|
Referent
|
1.09
|
0.98, 1.22
|
1.28
|
1.10, 1.47
|
No. of cases
|
336
|
609
|
179
|
Prostate volume ≥ 30 ccb
|
1.00
|
Referent
|
1.12
|
1.05, 1.20
|
1.04
|
0.94, 1.15
|
No. of cases
|
572
|
1058
|
241
|
25–29
|
Nocturiaa
|
1.40
|
1.03, 1.90
|
1.09
|
0.93, 1.28
|
1.25
|
1.08, 1.45
|
No. of cases
|
26
|
150
|
177
|
Prostate volume ≥ 30 ccb
|
0.94
|
0.73, 1.20
|
1.16
|
1.06, 1.26
|
1.10
|
1.00, 1.21
|
No. of cases
|
31
|
280
|
255
|
≥ 30
|
Nocturiaa
|
c
| |
c
| |
1.41
|
1.07, 1.86
|
No. of cases
| | |
33
|
Prostate volume ≥ 30 ccb
|
c
| |
1.61
|
1.32, 1.97
|
1.25
|
1.05, 1.48
|
No. of cases
| |
13
|
48
|
BMI at 50 (kg/m2)
| | | |
< 25
|
Nocturiaa
|
1.00
|
Referent
|
1.09
|
0.93, 1.28
|
c
| |
No. of cases
|
317
|
158
| |
Prostate volume ≥ 30 ccb
|
1.00
|
Referent
|
1.07
|
0.98, 1.18
|
c
| |
No. of cases
|
539
|
253
| |
25–29
|
Nocturiaa
|
1.04
|
0.80, 1.34
|
1.06
|
0.94, 1.19
|
1.30
|
1.13, 1.49
|
No. of cases
|
44
|
561
|
189
|
Prostate volume ≥ 30 ccb
|
0.87
|
0.72, 1.05
|
1.13
|
1.06, 1.21
|
1.06
|
0.96, 1.17
|
No. of cases
|
60
|
1029
|
252
|
≥ 30
|
Nocturiaa
|
c
| |
1.23
|
0.96, 1.58
|
1.21
|
1.05, 1.41
|
No. of cases
| |
44
|
195
|
Prostate volume ≥ 30 ccb
|
c
| |
1.16
|
1.00, 1.36
|
1.10
|
1.00, 1.21
|
No. of cases
| |
69
|
288
|
- BPH: benign prostatic hyperplasia; CI: Confidence Interval; BMI: body mass index; RR: risk ratio
- aAlso adjusted for time between completion of the baseline and supplemental questionnaires
- bAlso adjusted for number of DREs and time between participants’ first and last DRE
- cToo few cases (n ≤ 5) to estimate